These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 33322522)

  • 1. Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy.
    Boyero L; Sánchez-Gastaldo A; Alonso M; Noguera-Uclés JF; Molina-Pinelo S; Bernabé-Caro R
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33322522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment.
    Wang Q; Wu X
    Int Immunopharmacol; 2017 May; 46():210-219. PubMed ID: 28324831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients.
    Gkountakos A; Delfino P; Lawlor RT; Scarpa A; Corbo V; Bria E
    Ther Adv Med Oncol; 2021; 13():17588359211006947. PubMed ID: 34104224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome.
    Zou R; Wang Y; Ye F; Zhang X; Wang M; Cui S
    Clin Transl Oncol; 2021 Nov; 23(11):2237-2252. PubMed ID: 34002348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
    Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for small cell lung cancer: mechanisms of resistance.
    Hamilton G; Rath B
    Expert Opin Biol Ther; 2019 May; 19(5):423-432. PubMed ID: 30855195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Host-Related Factors as Targetable Drivers of Immunotherapy Response in Non-Small Cell Lung Cancer Patients.
    Baci D; Cekani E; Imperatori A; Ribatti D; Mortara L
    Front Immunol; 2022; 13():914890. PubMed ID: 35874749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response.
    Hijazi A; Antoniotti C; Cremolini C; Galon J
    Oncoimmunology; 2023; 12(1):2243169. PubMed ID: 37554310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies.
    To KKW; Fong W; Cho WCS
    Front Oncol; 2021; 11():635007. PubMed ID: 34113560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
    Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
    Front Immunol; 2021; 12():799455. PubMed ID: 35069581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer.
    Zhou K; Li S; Zhao Y; Cheng K
    Front Immunol; 2023; 14():1127071. PubMed ID: 36845142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis.
    Isomoto K; Haratani K; Tsujikawa T; Makutani Y; Kawakami H; Takeda M; Yonesaka K; Tanaka K; Iwasa T; Hayashi H; Ito A; Nishio K; Nakagawa K
    Lung Cancer; 2022 Dec; 174():71-82. PubMed ID: 36347190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance.
    Pu X; Wu L; Su D; Mao W; Fang B
    BMC Cancer; 2018 Nov; 18(1):1082. PubMed ID: 30409126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
    Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
    J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer.
    Wang M; Zhu L; Yang X; Li J; Liu Y; Tang Y
    Front Pharmacol; 2023; 14():1132158. PubMed ID: 36874015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors.
    Pezeshki PS; Mahdavi Sharif P; Rezaei N
    Expert Opin Biol Ther; 2021 Dec; 21(12):1575-1590. PubMed ID: 33984254
    [No Abstract]   [Full Text] [Related]  

  • 19. Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Frigola J; Navarro A; Carbonell C; Callejo A; Iranzo P; Cedrés S; Martinez-Marti A; Pardo N; Saoudi-Gonzalez N; Martinez D; Jimenez J; Sansano I; Mancuso FM; Nuciforo P; Montuenga LM; Sánchez-Cespedes M; Prat A; Vivancos A; Felip E; Amat R
    Mol Oncol; 2021 Apr; 15(4):887-900. PubMed ID: 33342055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to Checkpoint Inhibition in Cancer Immunotherapy.
    Barrueto L; Caminero F; Cash L; Makris C; Lamichhane P; Deshmukh RR
    Transl Oncol; 2020 Mar; 13(3):100738. PubMed ID: 32114384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.